Quest Diagnostics plans to add a new biomarker, Ki-67, to its Leumeta panel of plasma-based cancer tests. The Madison, New Jersey firm presented results from two studies of the marker at the annual meeting of the American Society of Hematology (ASH), held in New Orleans, Louisiana, in December ...
Please Login to read the full article.
